Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck/Lundbeck Gaboxadol NDA Planned For 2007; Merck Gets Fourth Phase III NME

This article was originally published in The Pink Sheet Daily

Executive Summary

The $270 mil. licensing deal with Lundbeck will help boost Merck's pipeline after two significant late-stage setbacks in 2003. The GABA-A receptor agonist gaboxadol would be Merck's entry into the sleep disorder market.

You may also be interested in...



Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia

Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.

Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia

Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.

Merck Gaboxadol Submission Delayed Until Mid-2007

Merck and its partner Lundbeck will not submit an NDA for the sleep aid in the first quarter, as previously planned.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS058571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel